Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Current Leases (2019 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Current Leases for 7 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • Quarterly Current Leases fell 45.96% to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, down 45.96% year-over-year, with the annual reading at $1.0 million for FY2025, 45.96% down from the prior year.
  • Current Leases hit $1.0 million in Q4 2025 for Rocket Pharmaceuticals, down from $1.0 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $1.9 million in Q2 2025 to a low of $792000.0 in Q2 2021.
  • Historically, Current Leases has averaged $1.4 million across 5 years, with a median of $1.7 million in 2021.
  • Biggest five-year swings in Current Leases: soared 130.36% in 2021 and later plummeted 49.37% in 2022.
  • Year by year, Current Leases stood at $863000.0 in 2021, then soared by 101.16% to $1.7 million in 2022, then increased by 3.17% to $1.8 million in 2023, then grew by 3.63% to $1.9 million in 2024, then plummeted by 45.96% to $1.0 million in 2025.
  • Business Quant data shows Current Leases for RCKT at $1.0 million in Q4 2025, $1.0 million in Q3 2025, and $1.9 million in Q2 2025.